Bui CN - Search Results

1

Comparative Efficacy of Venetoclax-Based Combination Therapies and Other Therapies in Treatment-Naive Patients With Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy: A Network Meta-Analysis.

Li X, Suh HS, Lachaine J, Schuh AC, Pratz K, Betts KA, Song J, Dua A, Bui CN. Li X, et al. Among authors: bui cn. Value Health. 2023 Dec;26(12):1689-1696. doi: 10.1016/j.jval.2023.09.001. Epub 2023 Sep 21. Value Health. 2023. PMID: 37741447

2

Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia.

Pratz KW, Panayiotidis P, Recher C, Wei X, Jonas BA, Montesinos P, Ivanov V, Schuh AC, DiNardo CD, Novak J, Pejsa V, Stevens D, Yeh SP, Kim I, Turgut M, Fracchiolla N, Yamamoto K, Ofran Y, Wei AH, Bui CN, Benjamin K, Kamalakar R, Potluri J, Mendes W, Devine J, Fiedler W. Pratz KW, et al. Among authors: bui cn. Blood Cancer J. 2022 Apr 20;12(4):71. doi: 10.1038/s41408-022-00668-8. Blood Cancer J. 2022. PMID: 35443742 Free PMC article.

3

Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.

Choi M, Song J, Bui CN, Ma E, Chai X, Yin L, Betts KA, Kapustyan T, Montez M, LeBlanc TW. Choi M, et al. Among authors: bui cn. J Manag Care Spec Pharm. 2022 Sep;28(9):980-988. doi: 10.18553/jmcp.2022.22021. Epub 2022 Jun 16. J Manag Care Spec Pharm. 2022. PMID: 35708343

4

Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis.

Guinan K, Mathurin K, Au Y, Schuh AC, Bui CN, Chai X, Lachaine J. Guinan K, et al. Among authors: bui cn. Curr Oncol. 2022 Oct 8;29(10):7524-7536. doi: 10.3390/curroncol29100592. Curr Oncol. 2022. PMID: 36290869 Free PMC article.

5

Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study.

Ito T, Sanford D, Tomuleasa C, Hsiao HH, Olivera LJE, Enjeti AK, Conca AG, Del Castillo TB, Girshova L, Martelli MP, Guvenc B, Bui CN, Delgado A, Duan Y, Guijarro BG, Llamas C, Lee JH. Ito T, et al. Among authors: bui cn. Eur J Haematol. 2022 Jul;109(1):58-68. doi: 10.1111/ejh.13769. Epub 2022 Apr 13. Eur J Haematol. 2022. PMID: 35298049 Free PMC article.

6

Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study.

Griffin JD, Yang H, Song Y, Kinrich D, Shah MV, Bui CN. Griffin JD, et al. Among authors: bui cn. Eur J Haematol. 2019 Apr;102(4):341-350. doi: 10.1111/ejh.13205. Epub 2019 Feb 5. Eur J Haematol. 2019. PMID: 30578743 Free PMC article.

7

Treatment patterns in patients with acute myeloid leukemia in the United States: a cross-sectional, real-world survey.

Medeiros BC, Pandya BJ, Hadfield A, Pike J, Wilson S, Mueller C, Bui CN, Flanders SC, Rider A, Horvath Walsh LE. Medeiros BC, et al. Among authors: bui cn. Curr Med Res Opin. 2019 May;35(5):927-935. doi: 10.1080/03007995.2019.1578152. Epub 2019 Mar 19. Curr Med Res Opin. 2019. PMID: 30712406

8

Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US.

Vachhani P, Flahavan EM, Xu T, Ma E, Montez M, Gershon A, Onishi M, Jin H, Ku G, Flores B, Bui CN, Abbas JA, Donnellan W. Vachhani P, et al. Among authors: bui cn. Oncologist. 2022 Nov 3;27(11):907-918. doi: 10.1093/oncolo/oyac135. Oncologist. 2022. PMID: 35925602 Free PMC article.

9

Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.

Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S. Massoudi M, et al. Among authors: bui cn. J Med Econ. 2017 Feb;20(2):121-128. doi: 10.1080/13696998.2016.1229670. Epub 2016 Sep 16. J Med Econ. 2017. PMID: 27570999 Free article.

10

Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs).

Zeidan AM, Mearns ES, Ng CD, Shah A, Lamarre N, Yellow-Duke A, Alrawashdh N, Yang B, Cheng WH, Bui CN, Svensson A. Zeidan AM, et al. Among authors: bui cn. Clin Lymphoma Myeloma Leuk. 2024 Mar;24(3):177-186. doi: 10.1016/j.clml.2023.10.010. Epub 2023 Oct 30. Clin Lymphoma Myeloma Leuk. 2024. PMID: 37996264 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters